

Importance of Specific Clinical Trial Enrollment Strategies for Native Hawaiian, Pacific Islander, and Asian Patients With Type 2 Diabetes Mellitus

PCR174



Taira DA^{1,2}; Ranken MS¹; Tengan K¹; Takata J¹; Porter C¹; Sentell TL^{1,2}; Suzuki M³; Hsieh J⁴; Lee CS⁴; Seto TB^{1,2}
¹The Queen's Medical Center, Honolulu, HI, USA; ²University of Hawai'i, Honolulu and Hilo, Hawai'i, USA; ³Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; ⁴Office of Minority Health and Health Equity, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA

INTRODUCTION

To develop drugs and devices that are safe and effective in all populations, clinical trials need to enroll a diverse range of participants.

OBJECTIVE

To explore Native Hawaiian, Pacific Islander, Asian (Filipino), and White patient views of specific clinical trial enrollment strategies

METHODS

- In-person, semi-structured interviews were conducted in English for a convenience sample of patients with type 2 diabetes mellitus, hospitalized in a large medical center in Hawaii.
- Interviews asked questions related to access, community engagement, and reducing trial burden.
- Rapid Qualitative Analysis was conducted to determine key takeaways for each subject area.

RESULTS

Table 1. Characteristics of Study Participants				
	Native Hawaiian (n = 17)	Pacific Islander (n =16)	Filipino (n = 15)	White (n = 8)
Age (mean±SD)	58.6±12.6	54.9±15.6	60.7±9.3	71.0±8.2
Female (%)	17.6%	62.5%	40.0%	50.0%
Born in US (%)	100.0%	18.8%	53.3%	100.0%
Education (%)				
<High school	11.8%	20.0%	0.0%	0.0%
High school	58.8%	46.7%	53.3%	37.5%
College	29.4%	33.3%	46.7%	37.5%
Graduate school	0.0%	0.0%	0.0%	25.0%

Importance of Each Factor to Clinical Trial Participation (% reporting its important)

Figure 1. Support by your **local healthcare providers**, such as your local doctors and nurses




Figure 2. **Location** of the clinical trial site




Figure 4. **Language assistance**




Figure 5. Access for persons with **disabilities**





Figure 6. Availability of **telehealth** visits



CONCLUSIONS

- Efforts to increase clinical trial diversity for Native Hawaiian, Pacific Islander, and Asian Filipino patients should include:
 - Local provider engagement
 - Efforts to decentralize study site locations
 - Telehealth options as most respondents from all populations expressed an interest in telehealth.
- Efforts for Pacific Islander and Filipino patients should also include language access and disability support.

FUNDING

This project is supported by the Food and Drug Administration (FDA) Office of Minority Health and Health Equity of the U.S. Department of Health and Human Services (HHS) (10903 New Hampshire Ave; Silver Spring, MD 20993) as part of a financial assistance award [FAIN U01FD007974] totaling \$499,514 with 100 percent funded by FDA OMHHE/HHS . The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.

CONTACT INFORMATION

Deborah Taira, ScD at dtjuarez@hawaii.edu